Mesothelioma, Malignant
31
12
15
7
Key Insights
Highlights
Success Rate
64% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.9%
4 terminated out of 31 trials
63.6%
-22.9% vs benchmark
0%
0 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (31)
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
SW-682 in Advanced Solid Tumors
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
......SMARTEST Trial......
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
HTL0039732 in Participants With Advanced Solid Tumours
A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Niraparib Efficacy in Patient With Unresectable Mesothelioma
First Local Anaesthesia Thoracoscopy for Pleural Effusion Diagnosis.
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies